Joan Miret

Joan Miret

Auto-generated profile, based on publicly available information

Joan Miret

Department of Chemical Biological and Environmental Engineering Universitat Autònoma de Barcelona Plaça Cívica Bellaterra 08193 Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2019 in mAbs
Verified
Journal Article
Open access
MFMercè Farràs
Mercè Farràs
JMJoan Miret
Joan Miret
MCMarc Camps
Marc Camps
RRRamón Román
Ramón Román
ÓMÓscar Martínez
Óscar Martínez
JCJordi Joan Cairó
Jordi Joan Cairó
Despite advances in medical care, cancer remains a major threat to human health. Antibody-drug conjugates (ADCs) are a promising targeted therapy to overcome adverse side effects to normal tissues. In this field, the current challenge is obtaining homogeneous preparations of conjugates, where a defined number of drugs are conjugated to specific antibody sites. Site-directed cysteine-based conjugation is commonly used to obtain homogeneous ADC, but it is a time-consuming and expensive approach due to the need for extensive antibody engineering to identify the optimal conjugation sites and reduction – oxidation protocols are specific for each antibody. There is thus a need for ADC platforms that offer homogeneity and direct applicability to the already approved antibody therapeutics. Here we describe a novel approach to derive homogeneous ADCs with drug-to-antibody ratio of 2 from any human immunoglobulin 1 (IgG1), using trastuzumab as a model. The method is based on the production of heavy chains (HC) and light chains (LC) in two recombinant HEK293 independent cultures, so the original amino acid sequence is not altered. Isolated LC was effectively conjugated to a single drug-linker (vcMMAE) construct and mixed to isolated HC dimers, in order to obtain a correctly folded ADC. The relevance of the work was validated in terms of ADC homogeneity (HIC-HPLC, MS), purity (SEC-HPLC), isolated antigen recognition (ELISA) and biological activity (HER2-positive breast cancer cells cytotoxicity assays).

1 July 2020 in Biochemical Engineering Journal
Verified
Journal Article
Closed access
JMJoan Miret
Joan Miret
RRRamón Román
Ramón Román
MBMario Benito
Mario Benito
ACAntoni Casablancas
Antoni Casablancas
Marina Guillén MontalbánMarina Guillén Montalbán
Marina Guillén Montalbán
GGGlòria González
Glòria González

27 November 2024 in Advanced Biology
Verified
Journal Article
Open access
Giacomo DomeniciGiacomo Domenici
Giacomo Domenici
Nuno LopesNuno Lopes
Nuno Lopes
GTGonçalo Trindade
Gonçalo Trindade
IGIsabella Ramella Gal
Isabella Ramella Gal
JMJoan Miret Minard
Joan Miret Minard
Catarina BritoCatarina Brito
Catarina Brito
Targeted, combinatorial, and immunomodulatory therapies, such as antibody‐drug conjugates (ADCs) and immunomodulatory antibodies (Abs), are powerful weapons against tumor cells and immune cells within the tumor microenvironment (TME). Therefore, the evaluation of such therapies should be conducted in pre‐clinical models able to recapitulate the complex cellular and molecular crosstalk of the TME. To build‐in critical hallmarks of the TME, a breast cancer heterotypic 3D cell model (3D‐3) is devised using a microencapsulation strategy with an inert biomaterial (alginate) and agitation‐based cultures. Both stromal and immune components are added to multicellular tumor spheroids, therefore fostering cancer‐associated fibroblasts (CAFs) and tumor‐associated macrophages (TAMs) immunomodulatory interactions. The potential of the methodology to assess Ab‐based therapies is then addressed by employing a series of anti‐HER2‐based ADCs. ADCs induced tumor‐cell specific cytotoxicity toward HER2+ breast cancer spheroids while sparing HER2‐negative CAFs. In addition, an immunomodulatory blocking Ab against colony‐stimulating factor 1 receptor (CSF1R) decreases the expression of immunosuppressive and anti‐inflammatory markers in TAMs, like what is previously observed upon in vivo α‐CSF1R administration. Collectively, the human TME‐based 3D‐3 cell model is a suitable tool to evaluate the anti‐tumor and immunomodulatory potential of novel antibody‐based therapies directed against TME targets, such as cancer cells and macrophages.

17 March 2020 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
JMJoan Miret
Joan Miret
MCMarc Camps
Marc Camps
MFMercè Farràs
Mercè Farràs
RRRamón Román
Ramón Román
SEStéphane Erb
Stéphane Erb
JCJordi J. Cairó
Jordi J. Cairó